Laboratorio de Toxicología Celular L-9, Unidad de Investigación Multidisciplinaria Universidad Nacional Autónoma de México, San Sebastián Xhala;, Email:
Laboratorio de Toxicología Celular L-9, Unidad de Investigación Multidisciplinaria Universidad Nacional Autónoma de México, San Sebastián Xhala.
Pharmazie. 2020 Jul 1;75(7):324-328. doi: 10.1691/ph.2020.0450.
Currently, cancer treatments are highly invasive, and they have been associated with a lot of adverse effects that put patient integrity at risk. Therefore, research of novel molecules and delivery systems capable of achieving a therapeutic effect that modifies inhibits and reduces the proliferative activity in cancer cells and, at the same time, reduce adverse effects associated with conventional therapies is imperative. In this study, we analyzed the biological effect of a novel cinnamic acid derivative, 3,4-dichlorobencil--phenoxylcilamide, in polymeric nanoparticles over MCF-7 breast cancer cells. The nanoparticulated system showed an inhibitory influence over cellular metabolism at equal or higher concentrations than 25 μM of 3,4-dichlorobencil--phenoxylcilamide, which is associated with PPARγ transcriptional activity, in addition to the decrease in the proliferation antigen Ki-67 basal levels. Those results position this kind of nanoscale system as an alternative on breast cancer treatment and lay the basis for research on the action mechanism associated with its cellular metabolism modulation and relationship with another hallmark on breast cancer cellular models.
目前，癌症治疗方法具有很强的侵入性，并且已经与许多不良反应相关联，这些不良反应会危及患者的完整性。因此，研究新型分子和能够实现治疗效果的输送系统至关重要，这些治疗效果可以调节、抑制和降低癌细胞的增殖活性，同时减少与传统疗法相关的不良反应。在这项研究中，我们分析了新型肉桂酸衍生物 3,4-二氯苯并苯氧乙基酰胺在聚合物纳米颗粒对 MCF-7 乳腺癌细胞的生物学效应。纳米颗粒系统在细胞代谢方面表现出抑制作用，其浓度与 25 μM 的 3,4-二氯苯并苯氧乙基酰胺相当，甚至更高，这与 PPARγ 转录活性有关，此外，还降低了增殖抗原 Ki-67 的基础水平。这些结果表明，这种纳米级系统是治疗乳腺癌的一种替代方法，并为研究与细胞代谢调节相关的作用机制以及与乳腺癌细胞模型的另一个标志之间的关系奠定了基础。
